Efficacy of moxifloxacin compared to teicoplanin in the treatment of implant-related chronic osteomyelitis in rats

Journal of Orthopaedic Research

Volumn 28, Issue 10, 2010, Pages 1368-1372

  Ozturan, Kutay Engin ^a   Yucel, Istemi ^b   Kocoglu, Esra ^a   Cakici, Husamettin ^a   Guven, Melih ^a  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

^b DUZCE UNIVERSITY   (Turkey)

Author keywords

Implant related chronic osteomyelitis; Moxifloxacin; Staphylococcus aureus; Teicoplanin

Indexed keywords

MOXIFLOXACIN; TEICOPLANIN; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; CHRONIC OSTEOMYELITIS; CONTROLLED STUDY; DRUG EFFICACY; IN VIVO STUDY; KIRSCHNER WIRE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CHRONIC DISEASE; COMPARATIVE STUDY; COMPLICATION; DISEASE MODEL; INTRAPERITONEAL DRUG ADMINISTRATION; MICROBIOLOGY; OSTEOMYELITIS; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FLUOROQUINOLONES; INJECTIONS, INTRAPERITONEAL; MALE; OSTEOMYELITIS; PROSTHESIS-RELATED INFECTIONS; QUINOLINES; RATS; RATS, WISTAR; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; TREATMENT OUTCOME;

EID: 77957190911     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21159     Document Type: Article

References (55)

1. Crémieux AC, Carbon C. 1997. Experimental models of bone and prosthetic joint infections. Clin Infect Dis 25:1295-1302.
2. Mader JT, Cripps MW, Calhoun JH. 1999. Adult posttraumatic osteomyelitis of the tibia. Clin Orthop Relat Res 360:14-21.
3. Lucke M, Wildemann B, Sadoni S, et al. 2005. Systemic versus local application of gentamicin in prophylaxis of implant-related osteomyelitis in a rat model. Bone 36:770-778.
4. Bauer TW, Schils J. 1999. The pathology of total joint arthroplasty: I. Mechanisms of implant fixation. Skeletal Radiol 28:423-432.
5. Bauer TW, Schils J. 1999. The pathology of total joint arthroplasty: II. Mechanisms of implant failure. Skeletal Radiol 28:483-497.
6. Periti P, Mini E, Mosconi G. 1998. Antimicrobial prophylaxis in orthopaedic surgery: the role of teicoplanin. J Antimicrob Chemother 41:329-340. (Pubitemid 28151981)
7. Periti P, Stringa G, Mini E. 1999. Comparative multicenter trial of teicoplanin versus cefazolin for antimicrobial prophylaxis in prosthetic joint implant surgery. Italian Study Group for Antimicrobial Prophylaxis in Orthopedic Surgery. Eur J Clin Microbiol Infect Dis 18:113-119.
8. Sugarman B, Young EJ. 1989. Infections associated with prosthetic devices: magnitude of the problem. Infect Dis Clin North Am 3:187-198.
9. Court-Brown CM. 1990. Antibiotic prophylaxis in orthopaedic surgery. Scand J Infect Dis Suppl 70:74-79.
10. Hill C, Flamant R, Mazas F, et al. 1981. Prophylactic cefazolin versus placebo in total hip replacement. Report of a multicentre double-blind randomised trial. Lancet 317:795-796.
11. Lidwell OM, Lowbury EJ, Whyte W, et al. 1984. Infection and sepsis after operations for total hip or knee-joint replacement: influence of ultraclean air, prophylactic antibiotics and other factors. J Hyg (Lond) 93:505-529.
12. Lambe DW Jr, Ferguson KP, Mayberry-Carson KJ, et al. 1991. Foreign-body-associated experimental osteomyelitis induced with Bacteroides fragilis and Staphylococcus epidermidis in rabbits. Clin Orthop 266:285-294.
13. Mayberry-Carson KJ, Tober-Meyer B, Smith JK, et al. 1984. Bacterial adherence and glycocalyx formation in osteomyelitis experimentally induced with Staphylococcus aureus. Infect Immun 43:825-833.
14. Costerton JW, Cheng KJ, Geesey GG, et al. 1987. Bacterial biofilms in nature and disease. Annu Rev Microbiol 41:435-464.
15. Gracia E, Fernández A, Conchello P, et al. 1997. Adherence of Staphylococcus aureus slime-producing strain variants to biomaterials used in orthopaedic surgery. Int Orthop 21:46-51.
16. Gracia E, Laclériga A, Monzón M, et al. 1998. Application of a rat osteomyelitis model to compare in vivo and in vitro the antibiotic efficacy against bacteria with high capacity to form biofilms. J Surg Res 79:146-153.
17. Gristina AG. 1994. Implant failure and the immunoincompetent fibroinflammatory zone. Clin Orthop 298:106-118.
18. Ince D, Zhang X, Hooper DC. 2003. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 47:1410-1415.
19. MacGowan AP. 1999. Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. Expert Opin Invest Drugs 8:181-199.
20. Allen GP, Kaatz GW, Rybak MJ. 2004. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int J Antimicrob Agents 24:150-160.
21. Firsov AA, Vostrov SN, Lubenko IY, et al. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 47:1604-1613.
22. Lister PD. 2001. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis 32:33-38.
23. Metzler K, Hansen GM, Hedlin P, et al. 2004. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 24:161-167.
24. Sierra JM, Cabeza JG, Ruiz Chaler M, et al. 2005. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clin Microbiol Infect 11:750-758.
25. Smith TL, Pearson ML, Wilcox KR, et al. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 340:493-501.
26. Kalteis T, Beckmann J, Schröder HJ, et al. 2006. Moxifloxacin superior to vancomycin for treatment of bone infections - a study in rats. Acta Orthop 77:315-319.
27. Kalteis T, Beckmann J, Schröder HJ, et al. 2006. Treatment of implant-associated infections with moxifloxacin: an animal study. Int J Antimicrob Agents 27:444-448.
28. Patel R, Piper KE, Rouse MS, et al. 2000. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob Agents Chemother 44:3438-3440.
29. Rouse MS, Piper KE, Jacobson M, et al. 2006. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 57:301-305.
30. Shirtliff ME, Calhoun JH, Mader JT. 2001. Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible Staphylococcus aureus osteomyelitis in rabbits. J Antimicrob Chemother 48:253-258.
31. Spagnolo N, Greco F, Rossi A, et al. 1993. Chronic staphylococcal osteomyelitis: a new experimental rat model. Infect Immun 61:5225-5230. (Pubitemid 23353902)
32. Yin LY, Lazzarini L, Li F, et al. 2005. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 55:995-1002.
33. Beck A, Kinzl L, Bischoff M. 1999. Antibiotic prophylaxis and therapy in trauma surgery. Unfallchirurg 102:955-966.
34. García-Alvarez F, Monzón M, Grasa JM, et al. 2006. Interleukin-1, interleukin-6, and interleukin-10 responses after antibiotic treatment in experimental chronic Staphylococcus aureus osteomyelitis. J Orthop Sci 11:370-374.
35. Krasemann C, Meyer J, Tillotson G. 2001. Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis 32:52-61.
36. Nawas BA, Shah MP. 1998. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 41:655-658. (Pubitemid 28279395)
37. Schmitz FJ, Hofmann B, Hansen B. 1998. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 41:481-484.
38. Von Eiff C, Peters G. 1999. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother 43:569-573.
39. Malincarne L, Ghebregzabher M, Moretti MV, et al. 2006. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. J Antimicrob Chemother 57:950-954.
40. Dan M, Keynan O, Feldbrin Z, et al. 2004. Concentrations of moxifloxacin in serum and synovial fluid, and ex-vivo bacterial activity against arthritis-causing pathogens. Diagn Microbiol Infect Dis 48:283-286.
41. Wise R, Andrews JM, Marshall G, et al. 1999. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 43:1508-1510. (Pubitemid 29259357)
42. Davey P, Williams A. 1991. Teicoplanin monotherapy of serious infections caused by gram-positive bacteria: a reevaluation of patients with endocarditis or Staphylococcus aureus bacteraemia from a European open trial. J Antimicrob Chemother 27:43-50.
43. Greenberg R. 1990. Treatment of bone, joint, and vascular-access- associated gram-positive bacterial infections with teicoplanin. Antimicrob Agents Chemother 34:2392-2397.
44. Greenwood D. 1988. Microbiological properties of teicoplanin. J Antimicrob Chemother 21:1-13.
45. Rowland M. 1990. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 18:184-209.
46. Williams A, Gruneberg R. 1984. Teicoplanin. J Antimicrob Chemother 14:441-445.
47. Atahan E, Gul M, Ergun Y, et al. 2007. Vascular graft infection by Staphylococcus aureus: efficacy of cefazolin, teicoplanin and vancomycin prophylaxis protocols in a rat model. Eur J Vasc Endovasc Surg 34:182-187.
48. Brin YS, Golenser J, Mizrahi B, et al. 2008. Treatment of osteomyelitis in rats by injection of degradable polymer releasing gentamicin. J Control Release 131:121-127.
49. Mader JT, Calhoun JH. 1990. Antimicrobial treatment of musculoskeletal infections. In: Evarts CM, editor. Surgery of the musculoskeletal systems. New York: Livingstone. p4323-4336.
50. Perry CR, Ritterbusch JK, Rice SH, et al. 1986. Antibiotics delivered by an implantable drug pump: a new application for treating osteomyelitis. Am J Med 80:222-227.
51. Adams K, Couch L, Cierny G, et al. 1992. In vitro and in vivo evaluation of antibiotic diffusion from antibiotic-impregnated polymethylmethacrylate beads. Clin Orthop 278:244-252.
52. Solberg BD, Gutow AP, Baumgaertner MR. 1999. Efficacy of gentamycin-impregnated resorbable hydroxyapatite cement in treating osteomyelitis in a rat model. J Orthop Trauma 13:102-106.
53. Orhan Z, Cevher E, Mulazimoglu L, et al. 2006. The preparation of ciprofloxacin hydrochloride-loaded chitosan and pectin microspheres: their evaluation in an animal osteomyelitis model. J Bone Joint Surg Br 88:270-275.
54. Orhan Z, Cevher E, Yildiz A, et al. 2010. Biodegradable microspherical implants containing teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. Arch Orthop Trauma Surg 130:135-142.
55. Schaumann R, Goldstein EJ, Forberg J, et al. 2005. Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. J Med Microbiol 54:749-753.